Literature DB >> 30418044

United States regulatory requirements for skin and eye irritation testing.

Neepa Y Choksi1, James Truax1, Adrienne Layton2, Joanna Matheson3, David Mattie4, Timothy Varney5, Jenny Tao6, Krystle Yozzo6, Andrew J McDougal7, Jill Merrill8, Donnie Lowther9, Joao Barroso10, Brenda Linke11, Warren Casey12, David Allen1.   

Abstract

PURPOSE: Eye and skin irritation test data are required or considered by chemical regulation authorities in the United States to develop product hazard labelling and/or to assess risks for exposure to skin- and eye-irritating chemicals. The combination of animal welfare concerns and interest in implementing methods with greater human relevance has led to the development of non-animal skin- and eye-irritation test methods. To identify opportunities for regulatory uses of non-animal replacements for skin and eye irritation tests, the needs and uses for these types of test data at U.S. regulatory and research agencies must first be clarified.
METHODS: We surveyed regulatory and non-regulatory testing needs of U.S. Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) agencies for skin and eye irritation testing data. Information reviewed includes the type of skin and eye irritation data required by each agency and the associated decision context: hazard classification, potency classification, or risk assessment; the preferred tests; and whether alternative or non-animal tests are acceptable. Information on the specific information needed from non-animal test methods also was collected.
RESULTS: A common theme across U.S. agencies is the willingness to consider non-animal or alternative test methods. Sponsors are encouraged to consult with the relevant agency in designing their testing program to discuss the use and acceptance of alternative methods for local skin and eye irritation testing.
CONCLUSIONS: To advance the implementation of alternative testing methods, a dialog on the confidence of these methods to protect public health and the environment must be undertaken at all levels.

Entities:  

Keywords:  Eye irritation testing; alternative approaches; corrosive; non-animal methods; regulatory requirements; skin irritation testing

Mesh:

Year:  2018        PMID: 30418044      PMCID: PMC6453729          DOI: 10.1080/15569527.2018.1540494

Source DB:  PubMed          Journal:  Cutan Ocul Toxicol        ISSN: 1556-9527            Impact factor:   1.820


  4 in total

1.  Improvement of the Bovine Corneal Opacity and Permeability (BCOP) assay as an in vitro alternative to the Draize rabbit eye irritation test.

Authors:  Sandra Verstraelen; An Jacobs; Bart De Wever; Philippe Vanparys
Journal:  Toxicol In Vitro       Date:  2013-03-14       Impact factor: 3.500

2.  Analysis of Draize eye irritation testing and its prediction by mining publicly available 2008-2014 REACH data.

Authors:  Thomas Luechtefeld; Alexandra Maertens; Daniel P Russo; Costanza Rovida; Hao Zhu; Thomas Hartung
Journal:  ALTEX       Date:  2016-02-11       Impact factor: 6.043

3.  Retrospective analysis of the Draize test for serious eye damage/eye irritation: importance of understanding the in vivo endpoints under UN GHS/EU CLP for the development and evaluation of in vitro test methods.

Authors:  Els Adriaens; João Barroso; Chantra Eskes; Sebastian Hoffmann; Pauline McNamee; Nathalie Alépée; Sandrine Bessou-Touya; Ann De Smedt; Bart De Wever; Uwe Pfannenbecker; Magalie Tailhardat; Valérie Zuang
Journal:  Arch Toxicol       Date:  2013-12-28       Impact factor: 5.153

4.  Advances in the Development and Validation of Test Methods in the United States.

Authors:  Warren M Casey
Journal:  Toxicol Res       Date:  2016-01-31
  4 in total
  2 in total

Review 1.  In vitro reconstructed 3D corneal tissue models for ocular toxicology and ophthalmic drug development.

Authors:  Yulia Kaluzhny; Mitchell Klausner
Journal:  In Vitro Cell Dev Biol Anim       Date:  2021-02-05       Impact factor: 2.416

Review 2.  Strategies to Develop a Suitable Formulation for Inflammatory Skin Disease Treatment.

Authors:  Jiun-Wen Guo; Shiou-Hwa Jee
Journal:  Int J Mol Sci       Date:  2021-06-04       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.